Sign in

Global Health Technologies Coalition (GHTC)

@ghtcoalition.org
148 followers 171 following 713 posts

Our mission is to advance innovation to save lives. GHTC is the leading advocacy organization working to accelerate R&D for #GlobalHealth technologies. #Innovate4Health

PostsRepliesMedia
Reposted by Global Health Technologies Coalition (GHTC)
Medicines for Malaria Venture (MMV) @mmv.org · 15h
Following encouraging Phase 2a results, MMV will lead the next phase of cabamiquine's development. Long-acting cabamiquine, with potential to become a single-dose treatment or prevention option, could help address drug resistance & block transmission: bit.ly/4ypoy9x
bit.ly
Promising long-acting malaria drug cabamiquine will move to next phase of development under MMV leadership | Medicines for Malaria Venture
001
Global Health Technologies Coalition (GHTC) @ghtcoalition.org · 9h
As AI continues to rapidly transform many aspects of technology and science, including health research, a new report from @who.int speaks to how stakeholders can help ensure AI-enabled health research is conducted responsibly and benefits everyone. www.ghtcoalition.org/blog/researc...
000
Global Health Technologies Coalition (GHTC) @ghtcoalition.org · 30/09/2026
What’s the difference between a patent pool and a pooled fund? Check out our #GlobalHealth R&D dictionary to learn more. 🌍🕮 www.ghtcoalition.org/global-healt...
000
Reposted by Global Health Technologies Coalition (GHTC)
CEPI @cepi.net · 30/09/2026
As global health leaders ready themselves for this year’s World Health Summit Health Summit in Berlin, CEPI invites you to join its official panel discussion, From Crisis Response to Resilience: Innovating for Health Security Beyond Borders. Register: www.worldhealthsummit.org/sessions/034...
001
Global Health Technologies Coalition (GHTC) @ghtcoalition.org · 30/09/2026
The first participants have been vaccinated in a trial in the DRC, where the country’s ongoing outbreak of the #Bundibugyo strain of #Ebola has now become the largest Ebola outbreak in the country’s history and the second largest in history. www.ghtcoalition.org/blog/researc...
000
Reposted by Global Health Technologies Coalition (GHTC)
Global Antibiotic R&D Partnership (GARDP) @gardp.bsky.social · 29/09/2026
🤝 GARDP and @dndi.org are pleased to announce support from the Foundation for the Adaptation of International Geneva to strengthen collaboration, share capabilities and resources, and help both focus more on developing and ensuring access to treatments for NTDs and drug-resistant infections.
122
Reposted by Global Health Technologies Coalition (GHTC)
CEPI @cepi.net · 29/09/2026
New funding: The @bioprevail.bsky.social x CEPI Biosecurity Innovation Challenge is seeking practical biosafety and biosecurity innovations to strengthen vaccine R&D and manufacturing during epidemic and pandemic responses, supporting CEPI’s 100 Days Mission: bioprevail.org/challenge/bi...
111
Global Health Technologies Coalition (GHTC) @ghtcoalition.org · 29/09/2026
Recent results from a trial testing a new regimen for people with chronic T. cruzi infection could offer a safer, more practical treatment option for the infection, which affects more than seven million people globally. www.ghtcoalition.org/blog/researc...
001
Global Health Technologies Coalition (GHTC) @ghtcoalition.org · 28/09/2026
What's new in #GlobalHealth R&D? 💊Shorter #Chagas treatment regimen 💉 #Ebola vaccine trial 🖥️AI in health research report www.ghtcoalition.org/blog/researc...
ghtcoalition.org
Research Roundup: Shorter Chagas regimen, Ebola vaccine trial, AI in health research report
In this regular feature on Breakthroughs, we highlight some of the most interesting reads in global health research from the past week.
011
Global Health Technologies Coalition (GHTC) @ghtcoalition.org · 25/09/2026
Ensuring everyone globally who wishes to use contraception has access to safe, effective, and acceptable options will require a variety of new and improved contraceptive choices. Check out some tools in pipeline! #WorldContraceptionDay www.ghtcoalition.org/blog/world-c...
000
Global Health Technologies Coalition (GHTC) @ghtcoalition.org · 24/09/2026
@cepi.net recently announced that it is awarding $3.9 million to support research projects aimed at improving understanding of the #Bundibugyo ebolavirus behind the ongoing outbreak in the Democratic Republic of the Congo. www.ghtcoalition.org/blog/researc...
ghtcoalition.org
Research Roundup: Investigational once-yearly HIV prevention planning, Newborn antimalarial rollout, Bundibugyo Ebola research
In this regular feature on Breakthroughs, we highlight some of the most interesting reads in global health research from the past week.
000
Global Health Technologies Coalition (GHTC) @ghtcoalition.org · 23/09/2026
US funding changes in 2025 stalled a range of promising #GlobalHealth R&D efforts, disrupting ongoing work to advance critical innovations across the United States and worldwide. Explore these impacts in our Innovation Interrupted tool. bit.ly/3RKTkcK
010
Global Health Technologies Coalition (GHTC) @ghtcoalition.org · 23/09/2026
At #UNGA80 ahead of the PPPR HLM, our conversations reinforced a key message: pandemic preparedness & innovation go hand in hand. A discussion we hosted with Adjuvant Capital, State Dept officials, & partners explored the systems, technologies, & partnerships needed to strengthen preparedness.
000
Global Health Technologies Coalition (GHTC) @ghtcoalition.org · 23/09/2026
@who.int has updated its malaria guidelines to include Coartem Baby, the first antimalarial developed specifically for newborns and young infants weighing between two and five kilograms, a group that previously had no medicine specifically designed for them. www.ghtcoalition.org/blog/researc...
ghtcoalition.org
Research Roundup: Investigational once-yearly HIV prevention planning, Newborn antimalarial rollout, Bundibugyo Ebola research
In this regular feature on Breakthroughs, we highlight some of the most interesting reads in global health research from the past week.
000
Global Health Technologies Coalition (GHTC) @ghtcoalition.org · 22/09/2026
Last week, Gilead announced that it has expanded its voluntary licensing agreements with partners, who are already manufacturing the recently approved twice-yearly #lenacapavir for #HIV prevention, to include investigational once-yearly lenacapavir. www.ghtcoalition.org/blog/researc...
011
Reposted by Global Health Technologies Coalition (GHTC)
CEPI @cepi.net · 21/09/2026
🔉 Major new funding for CEPI announced today. Ethiopia, Norway and the UK have pledged a combined US$240 million to support CEPI’s five-year plan to transform the world’s ability to prevent and respond to future epidemic and pandemic threats. cepi.net/ethiopia-nor...
163
Global Health Technologies Coalition (GHTC) @ghtcoalition.org · 21/09/2026
What's new in #GlobalHealth R&D? 💉Investigational once-yearly #HIV prevention planning 💊Newborn #malaria drug rollout 🥼#Bundibugyo Ebola research t.co/piZZWvhcII
000
Reposted by Global Health Technologies Coalition (GHTC)
Drugs for Neglected Diseases initiative (DNDi) @dndi.org · 18/09/2026
Join us at #UNGA81 to discuss how to better prepare for pandemics through R&D & the 100 Days Mission. The 100 Days Mission aims to ensure the development & delivery of diagnostics, therapeutics, & vaccines within 100 days of a pandemic threat being identified. 🕗 8:00–9:30 a.m. ET 🔗 dvx.cm/bgxtab
002
Global Health Technologies Coalition (GHTC) @ghtcoalition.org · 18/09/2026
New longer-acting, multipurpose #HIV products, like injectables & vaginal rings, in the pipeline could revolutionize care by providing discreet, convenient prevention against HIV & pregnancy. Learn more about these breakthroughs!💊⭕️➡️bit.ly/HIVFS
000
Reposted by Global Health Technologies Coalition (GHTC)
CARB-X @carb-x.bsky.social · 17/09/2026
CARB-X is pleased to support @sniprbiome.com Phase 2a trial for SNIPR001. Through a targeted investment in this study, CARB-X is supporting the generation of proof-of-efficacy data needed to help advance SNIPR001 toward patients. #IDSky 🧪 Read below.
021
Reposted by Global Health Technologies Coalition (GHTC)
AVAC @avac.org · 17/09/2026
Join us September 30 for a global webinar to hear the latest updates on the #bNAb pipeline and to discuss what the future holds. 🔗 avac.org/event/whats-... #HIV #HIVprevention #CAPRISA
065
Global Health Technologies Coalition (GHTC) @ghtcoalition.org · 17/09/2026
Immunoscript Life Science will receive up to $8.9 million from @cepi.net to further development of its thermostable next-generation self-amplifying RNA (saRNA) vaccine platform, which could help improve access to RNA vaccines globally. www.ghtcoalition.org/blog/researc...
ghtcoalition.org
Research Roundup: Multi-dose RSV vaccine, Nanobody-based snakebite treatment, Thermostable RNA vaccine
In this regular feature on Breakthroughs, we highlight some of the most interesting reads in global health research from the past week.
000
Global Health Technologies Coalition (GHTC) @ghtcoalition.org · 16/09/2026
#DYK: Over 1 billion people globally are affected by neglected diseases. There remains an urgent need for new technologies to fight longstanding and emerging threats. #GlobalHealth 👇🏼 www.ghtcoalition.org/why-research...
010
Global Health Technologies Coalition (GHTC) @ghtcoalition.org · 16/09/2026
The rise in fungal diseases is slowly attracting greater attention, but the pace of innovation lags behind the scale of the threat. There is an urgent need for greater investment in the R&D of fit-for-purpose innovations for the most dangerous pathogens. www.ghtcoalition.org/blog/fungal-...
010
Global Health Technologies Coalition (GHTC) @ghtcoalition.org · 16/09/2026
A research team has developed a nanobody-based antivenom that could provide a more flexible and effective approach for treating snakebites, which kill tens of thousands of people globally and disable hundreds of thousands more. www.ghtcoalition.org/blog/researc...
000
Global Health Technologies Coalition (GHTC) @ghtcoalition.org · 16/09/2026
In response to the growing global threat of fungal disease, there is an urgent need for new diagnostic tools, including simple, multi-pathogen, & minimally invasive tools, to improve access in resource-constrained settings that face heightened risk. www.ghtcoalition.org/blog/fungal-...
ghtcoalition.org
Fungal diseases are rising. Innovation must keep up.
Fungal diseases are a growing global health threat, driven in part by the rise in antifungal resistance. A persistent lack of attention and investment has fueled gaps in innovation, but several promis...
000
Global Health Technologies Coalition (GHTC) @ghtcoalition.org · 15/09/2026
Last week, @who.int prequalified multi-dose vials of the maternal vaccine against RSV, enabling rollout in lower-income countries. www.ghtcoalition.org/blog/researc...
000
Reposted by Global Health Technologies Coalition (GHTC)
Medicines for Malaria Venture (MMV) @mmv.org · 15/09/2026
Different patients need medicines designed for their particular needs. Coartem® Baby, the first antimalarial developed for newborns and young infants weighing 2–5 kg, is now included in the WHO Guidelines for #malaria, supporting broader access. Read more: bit.ly/4iqa5Fr
bit.ly
WHO Guidelines for malaria now include Coartem® Baby for newborns and young infants | Medicines for Malaria Venture
001
Global Health Technologies Coalition (GHTC) @ghtcoalition.org · 14/09/2026
Despite the significant and growing global burden of fungal disease, the pipeline of new antifungal therapies remains thin. Recent trial results and a promising approach in early development demonstrate the potential for R&D to transform treatment. www.ghtcoalition.org/blog/fungal-...
ghtcoalition.org
Fungal diseases are rising. Innovation must keep up.
Fungal diseases are a growing global health threat, driven in part by the rise in antifungal resistance. A persistent lack of attention and investment has fueled gaps in innovation, but several promis...
010
Reposted by Global Health Technologies Coalition (GHTC)
Medicines for Malaria Venture (MMV) @mmv.org · 14/09/2026
Does your organization have insights into how AI can improve clinical trial design and documentation? MMV, @dndi.org and @gardp.bsky.social are mapping AI solutions for clinical study design, operations and medical writing. Submission deadline: 7 October Learn more: bit.ly/3UMwkeW
022
Global Health Technologies Coalition (GHTC) @ghtcoalition.org · 14/09/2026
What's new in #GlobalHealth R&D? 💉Multi-dose RSV vaccine 🐍Nanobody-based snakebite treatment 🧊Thermostable RNA vaccine www.ghtcoalition.org/blog/researc...
ghtcoalition.org
Research Roundup: Multi-dose RSV vaccine, Nanobody-based snakebite treatment, Thermostable RNA vaccine
In this regular feature on Breakthroughs, we highlight some of the most interesting reads in global health research from the past week.
011
Reposted by Global Health Technologies Coalition (GHTC)
Global Antibiotic R&D Partnership (GARDP) @gardp.bsky.social · 14/09/2026
Newly published GARDP-sponsored research offers encouraging evidence for expanding treatment options for newborns with sepsis. 🔗 pubmed.ncbi.nlm.nih.gov/42705380/ #AMR #GARDP
pubmed.ncbi.nlm.nih.gov
In vitro activity of flomoxef, fosfomycin and amikacin versus a global panel of third-generation cephalosporin-resistant Enterobacterales and prediction of their ability in pairwise combinations to work as carbapenem-sparing regimens - PubMed
The results confirm the potential of these combinations as carbapenem-sparing treatments and provide additional evidence to support the evaluation of these combinations in the neonatal sepsis trial that is sponsored by GARDP (ISRCTN48721236).
101
Global Health Technologies Coalition (GHTC) @ghtcoalition.org · 11/09/2026
NIH researchers have discovered rare antibodies that could inform the development of a therapeutic or preventive intervention for alpha-gal syndrome. The discovery was made through malaria research. www.ghtcoalition.org/blog/researc...
000
Global Health Technologies Coalition (GHTC) @ghtcoalition.org · 11/09/2026
Fungal diseases are a growing #GlobalHealth threat, driven partly by rising resistance. Under-prioritization has fueled innovation gaps, but new treatments & diagnostics demonstrate the potential for R&D to transform the global response. #ThinkFungus26 www.ghtcoalition.org/blog/fungal-...
ghtcoalition.org
Fungal diseases are rising. Innovation must keep up.
Fungal diseases are a growing global health threat, driven in part by the rise in antifungal resistance. A persistent lack of attention and investment has fueled gaps in innovation, but several promis...
000
Global Health Technologies Coalition (GHTC) @ghtcoalition.org · 10/09/2026
A Phase 2 clinical trial led by the Serum Institute of India found that an experimental monoclonal antibody for #dengue virus was safe, well-tolerated, and provided evidence of efficacy in a Phase 2 clinical trial. www.ghtcoalition.org/blog/researc...
010
Reposted by Global Health Technologies Coalition (GHTC)
CEPI @cepi.net · 09/09/2026
Today we announced new funding of up to US$8.9 million in Immunoscript Life Science to advance clinical testing of its thermostable next-generation self-amplifying RNA vaccine technology 🔽
cepi.net
India ramps up Disease X preparedness with $8.9 million funding boost for its freezer-free RNA vaccine
The funding will advance clinical testing of Immunoscript's thermostable next-generation RNA vaccine platform.
011
Global Health Technologies Coalition (GHTC) @ghtcoalition.org · 09/09/2026
When #GlobalHealth research is interrupted, the effects are cascading. Researchers, institutions, partnerships, and communities across the US and globally all feel the impact. Explore our new Innovation Interrupted tool: bit.ly/3RKTkcK
000
Global Health Technologies Coalition (GHTC) @ghtcoalition.org · 09/09/2026
Last week, Cepheid announced that its Xpert Hemorrhagic Fever Panel test has received Emergency Use Listing from WHO, enabling the technology to be deployed in the rapidly growing outbreak of Bundibugyo #Ebola. www.ghtcoalition.org/blog/researc...
ghtcoalition.org
Research Roundup: Emergency listing for Ebola test, Dengue monoclonal antibody trial, Alpha-gal syndrome discovery
In this regular feature on Breakthroughs, we highlight some of the most interesting reads in global health research from the past week.
000
Global Health Technologies Coalition (GHTC) @ghtcoalition.org · 08/09/2026
The Fogarty International Center at NIH forges international health research partnerships that push science forward and make us all safer, accelerating new technologies and innovations for health challenges that affect Americans and people around the world. www.healthaffairs.org/content/fore...
healthaffairs.org
Health Affairs Journal
000
Global Health Technologies Coalition (GHTC) @ghtcoalition.org · 08/09/2026
What's new in #GlobalHealth R&D? 🚨Emergency listing for #Ebola test 🦟#Dengue monoclonal antibody trial 🔬Alpha-gal syndrome discovery through #malaria research www.ghtcoalition.org/blog/researc...
ghtcoalition.org
Research Roundup: Emergency listing for Ebola test, Dengue monoclonal antibody trial, Alpha-gal syndrome discovery
In this regular feature on Breakthroughs, we highlight some of the most interesting reads in global health research from the past week.
000
Global Health Technologies Coalition (GHTC) @ghtcoalition.org · 04/09/2026
What’s the difference between a patent pool and a pooled fund? Check out our #GlobalHealth R&D dictionary to learn more. 🌍🔬🕮 www.ghtcoalition.org/global-healt...
000
Global Health Technologies Coalition (GHTC) @ghtcoalition.org · 03/09/2026
A novel #TB vaccine candidate failed to match the current, more-than-100-years-old vaccine in preventing TB infections in newborns, according to the recently shared results of a Phase 3 trial conducted among 6,897 healthy newborns in sub-Saharan Africa. www.ghtcoalition.org/blog/researc...
000
Reposted by Global Health Technologies Coalition (GHTC)
Drugs for Neglected Diseases initiative (DNDi) @dndi.org · 03/09/2026
Join us for a discussion on the growing practice of Access Planning in R&D, examining how it can help ensure that publicly funded R&D translates into timely public health-driven innovation and accessible, affordable, and available resulting health technologies. docs.google.com/forms/d/e/1F...
002
Reposted by Global Health Technologies Coalition (GHTC)
WHO @who.int · 03/09/2026
Good news! Congrats to #TimorLeste for eliminating trachoma as a public health problem. It was the last country in WHO’s South-East Asia Region with suspected endemic trachoma. With this milestone, #trachoma has now been eliminated as a public health problem from the region bit.ly/4yjvp45
A healthcare worker in a green shirt examines an elderly woman's eye using a handheld device in a crowded clinic.
111026
Reposted by Global Health Technologies Coalition (GHTC)
Global Antibiotic R&D Partnership (GARDP) @gardp.bsky.social · 02/09/2026
📅 Save the date: 9–11 Feb 2027 The #ACC2027 is a free, open-access virtual conference, jointly organised by @bsacandjac.bsky.social and GARDP within the framework of the @eupohamr.bsky.social. More info coming soon! 🌐Explore the website: acc-conference.com
024
Reposted by Global Health Technologies Coalition (GHTC)
Medicines for Malaria Venture (MMV) @mmv.org · 02/09/2026
MMV has launched a request for information to identify organizations based in or operating in malaria-endemic countries for a new request for information on #malaria market intelligence and evidence generation. Deadline: 14 October Learn more: bit.ly/4cbgujY
011
Reposted by Global Health Technologies Coalition (GHTC)
Devex @devex.com · 02/09/2026
Dr. Osamu Kunii, CEO of GHIT Fund, says he saw an opportunity to invest in pandemic-related innovations post-COVID-19, in particular diagnostics and antivirals.
devex.com
Japan-based health tech fund broadens portfolio to include pandemics
Japan-based health tech fund broadens portfolio to include pandemics
001
Global Health Technologies Coalition (GHTC) @ghtcoalition.org · 02/09/2026
Our six-part US agency fact sheet series examines the contributions of key US agencies to #GlobalHealth R&D, looking at each agency’s unique role, how it invests across health areas, and success stories of its impact. Check it out ⬇️ www.ghtcoalition.org/resources-it...
000
Global Health Technologies Coalition (GHTC) @ghtcoalition.org · 02/09/2026
Last week, @cepi.net announced that it will invest up to $16.5 million to advance the development of an African-developed vaccine candidate for #Bundibugyo Ebola, which is behind the fast-growing outbreak in the Democratic Republic of the Congo. www.ghtcoalition.org/blog/researc...
000
Global Health Technologies Coalition (GHTC) @ghtcoalition.org · 01/09/2026
@gatesfoundation.bsky.social has awarded ProFound up to $35 million to find new drug targets for preeclampsia, a high blood pressure pregnancy condition that can be severe for mother & child and contributes significantly to maternal & fetal deaths globally. www.ghtcoalition.org/blog/researc...
ghtcoalition.org
Research Roundup: Preeclampsia R&D funding, Bundibugyo vaccine trial support, TB vaccine underperforms in trial
In this regular feature on Breakthroughs, we highlight some of the most interesting reads in global health research from the past week.
000